Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

NCT02044328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.